Association between Antiphospholipid Antibodies (APLA) and Preeclampsia (PE) in Females Presenting for Antenatal Check-Up

Farsom Ayub¹, Maryam Talib², Muhammad Arslan Iqbal³
¹WMO at BHU 34-3R, Haroonabad, District Bahawalnagar
²Women Medical Officer at BHU Hajiwala, Gujrat
³Nishtar Medical College, Multan

ABSTRACT

Introduction: APLA have been associated with a number of obstetric complications however their role in the pathogenesis of preeclampsia has remained an issue of controversy. There is a lack of information on APLA in pre-eclamptic women.

Objective: To assess the association between antiphospholipid antibodies (APLA) and preeclampsia (PE) in females presenting for antenatal check-up.

Materials and Methods: This Case Control study was conducted in Services Institute of Lahore. After approval from hospital ethical committee, 200 females, fulfilling the inclusion criteria were included in the study from OPD of Department of Obstetrics & Gynecology. Informed consent was obtained. Demographic information was also recorded. The females were divided in two groups on the basis of presence or absence of PE i.e. cases and controls.

Results: The mean age of the patients among cases was 27.60±4.96 years the minimum age was 20 years and maximum was 35 years whereas among controls the mean age of the patients was 27.94±4.13 years the minimum age was 20 years and maximum was 35 years. The mean gestational age among cases was 27.46±4.72 weeks the minimum gestational age was 20 weeks and maximum was 35 weeks on the other side the mean gestational age among controls was 27.25±4.74 weeks the minimum gestational age was 20 weeks the maximum was 35 weeks. There was significant association between preeclampsia and APLA as the p-value was significant (p-value=0.007).

Conclusion: Results of this study showed a significant association and significant risk between APLA and preeclampsia. Therefore a routine assay of APLA in women at risk of preeclampsia should be done. However APLA testing should be considered in women with early onset severe preeclampsia, especially when additional clinical features of APS are present.

KEY WORDS: Antiphospholipid Antibodies (APLA), Antenatal Check-up, Preeclampsia (PE)

INTRODUCTION

Antiphospholipid antibodies (APLA) are a group of auto-antibodies that have the ability to bind to cardiolipin alone, to cardiolipin complexed to a cofactor or to a cofactor alone. APLA are found in up to 5% of healthy subjects in the general population. The prevalence of APLA in the low risk obstetrical population ranges from 1-9%. APLA promote activation of endothelial cells, monocytes, and platelets; and overproduction of tissue factor and thromboxane A2. Complement activation might have a central pathogenetic role.

Antiphospholipid syndrome (APS) is associated with adverse pregnancy outcomes including preeclampsia, recurrent early pregnancy loss, fetal death, and intrauterine growth restriction. Approximately one third of women with APS will develop preeclampsia during pregnancy. Antiphospholipid syndrome was first described 27 years ago in patients with systemic lupus erythematosus (SLE) and positive antcardiolipin antibodies, who presented with a clotting syndrome that affected arteries and veins. Female patients had a high risk of recurrent miscarriage and late fetal loss. Current evidence does not justify inclusion of preeclampsia as a major criterion for APS, but preeclampsia could reasonably be included as a secondary or minor criterion in diagnosis when a patient has other clinical features of APS.

The presence of antiphospholipid antibodies (APLA) especially antcardiolipin antibodies increased pregnancy risk, as 59.1% IgG or IgM antibodies to one of the six phospholipids (cardiolipin, APS,APLA, phosphoglycerol and phosphatidicacid) were seen as compared to controls (4.6%). Benedict et al., also found that insignificant difference observed between preeclamptic and control
females for presence of APLA i.e. 10% in preeclampsia group and 0% in control group. Dreyfus reported no association between antiphospholipid antibodies and preeclampsia. The OR for the association was 0.95 (95% CI 0.45, 2.61). APLA were detected 4.4% (8/180) PE women and in 5.3% (19/360) controls. Rationale of this study is to determine the association of APLA with PE in females presenting in a tertiary care setting for antenatal check-up. Literature has showed that there is significant association between APLA and PE but there are also contradictions present regarding association of APLA with PE. So we planned this study to find whether there is any impact of APLA for development of PE. Moreover, not much data is available and no local data was found in literature. So we aimed to conduct this study to find local magnitudes and can be able to detect increase in APLA in pregnant females in early gestational age and can prevent PE.

OBJECTIVE
To assess the association between antiphospholipid antibodies (APLA) and preeclampsia (PE) in females presenting for antenatal check-up.

MATERIALS AND METHODS
This Case Control study was conducted in Services Institute of medical sciences, Lahore. The data was collected through Non-probability consecutive sampling technique.

Sample Size
A sample size of 200 (100 in each group) with 80% power of test and 5% level of significance and taking expected percentage of APLA i.e.10% in females having PE and 0% in females without PE.

Inclusion Criteria
- Age of patient between 20-35 years of any parity
- Singleton pregnancy of gestational age ≥20weeks (on USG)
- CASES
  - Females with PE (as per operational definition)
- CONTROL
  - Females without PE presenting for antenatal routine checkup

Exclusion Criteria
- Females with chronic hypertension (BP≥140/90mmHg) before pregnancy
- Females with chronic or gestational diabetes (BSR>200mg/dl)
- Females with recurrent spontaneous miscarriages, history of deep vein thrombosis and autoimmune disease
- Females on anticoagulant therapy and coagulation factor deficiencies in pre-pregnancy
- Females with infectious diseases (HIV inclusive) and malignancies (on medical record)

Data Collection Procedure
After approval from hospital ethical committee, 200 females, fulfilling the inclusion criteria were included in the study from OPD of Department of Obstetrics & Gynecology. Informed consent was obtained. Demographic information (name, age, gestational age, parity and address) was also recorded. The females were divided in two groups on the basis of presence or absence of PE i.e. cases and controls. Blood sample of 12mls were collected from the antecubital vein of each of the study subject and was sent to the laboratory of the hospital to assess APLA (as per operational definition). Reports were assessed to label APLA positive or negative. All this information was recorded on proforma (attached).

Data Analysis
Data was analyzed in SPSS version 20. Mean ± SD was calculated for age and gestational age. Frequency was measured for parity. Odds Ratio was calculated to measure association between APLA and PE. OR>1 was considered statistically significant. Data was stratified for age and parity. Post stratification OR was calculated. OR>1 was considered significant.
RESULTS

Mean age of the patients among cases was 27.60±4.96 years the minimum age was 20 years and maximum was 35 years whereas among controls the mean age of the patients was 27.94±4.13 years the minimum age was 20 years and maximum was 35 years. (Table-1)

Table-1: Descriptive statistics for age

|        | Cases       | Controls    |
|--------|-------------|-------------|
| n      | 100         | 100         |
| Mean   | 27.60       | 27.94       |
| Std. Deviation | 4.96       | 4.139       |
| Minimum | 20         | 20          |
| Maximum | 35         | 35          |

Cases: Females with PE (as per operational definition)

Control: Females without PE presenting for antenatal routine checkup

The mean gestational age among cases was 27.46± 4.72 weeks the minimum gestational age was 20 weeks and maximum was 35 weeks on the other side the mean gestational age among controls was 27.25± 4.74 weeks the minimum gestational age was 20 weeks the maximum was 35 weeks. Among cases there were 46() women whose parity was 1, 36 women’s parity was 2 and 18 women’s parity was 3 whereas among controls there were 28 () women’s whose parity was 1, 48 women’s parity was 2 and 24 women’s parity was 2.

Graph-1: Parity Status of Women
Among cases there were 17 (17%) women in which Antiphospholipid antibodies were present where as in 83 (83%) APLA was absent, among controls there were 5(5%) women in which Antiphospholipid antibodies were present where as among 95 (95%) APLA was absent. There was significant association between preeclampsia and Antiphospholipid antibodies (APLA) as the p-value was significant (p-value=0.007). The odds ratio is 3.89 which means there are 3.89 time more odds of having preeclampsia if APLA is present in women. (OR=3.89)

Table-2: Association between APLA & preeclampsia

| Group | Case   | Control | Total |
|-------|--------|---------|-------|
| APLA  | Present| 17(17%) | 5(5%) | 22    |
|       | Absent | 83(83%) | 95(95%) | 178   |
| Total |        | 100     | 100   | 200   |

There was significant association between APLA and preeclampsia in the age group of 20-28 years as the p-value was significant. (p-value= 0.041) there are 3.34 times more odds of developing preeclampsia in this age group if patient have APLA (OR=3.34) whereas in the age group of 29-36 years there was no significant association between APLA and preeclampsia as the p-value was not significant (p-value=0.066) there are 5.87 times more Odds of developing preecampsia is the APLA is present in patient.

Table-3: Association between APLA and preeclampsia stratified for age groups

| Age Groups | 20-28 Years | 29-36 Years |
|------------|-------------|------------|
| APLA       | Case        | Control    | Case | Control |
| Present    | 12(%)       | 4(%)       | 5(%) | 1(%) |
| Absent     | 43(%)       | 48(%)      | 40(%) | 47(%) |
| Total      | 55          | 52         | 45    | 48    |
| Chi-Square Test | 4.19     | 3.38       |
| p-value    | 0.041        | 0.066       |
| Odds Ratio | 3.34         | 5.87        |

There was no significant association between APLA and preeclampsia among the women whose party was 1 but there were 4.08 times more odds of developing Preeclampsia among those women in which APLA was present where as among women whose parity was 2 there was also no significant association between preeclampsia and APLA and there were 2.09 times more odds of developing preeclampsia if the APLA was present lastly women with parity 3 there was no significant association between Preeclampsia and APLA and there were 4.6 times more odds of developing preeclampsia if APLA was present.

Table-4: Association between APLA & Preeclampsia Stratified For Parity

| Parity | 1 | 2 | 3 |
|--------|---|---|---|
|        | Case | Control | Case | Control | Case | Control |
| APLA   | Present | 11(%) | 2(%) | 3(%) | 2(%) | 3(%) | 1(%) |
|        | Absent  | 35(%) | 26(%) | 33(%) | 46(%) | 15(%) | 23(%) |
| Total  |        | 46    | 28    | 36    | 48    | 18    | 24    |
| Chi-Square Test | 3.38       | 0.63       | 1.88       |
| p-value | 0.066       | 0.24       | 0.17       |
| Odds Ratio | 4.08        | 2.09        | 4.6        |
DISCUSSION

APLA constitute a heterogeneous group of circulating antibodies against anionic phospholipids with the most important ones being anticardiolipin antibodies, anti-β2-glycoprotein I (β2 GP I) and lupus anticoagulants. In relation to pregnancy, they are association with recurrent fetal loss and complications such as preeclampsia retarded fetal growth or placental insufficiency.

Preeclampsia is defined as the onset of proteinuric hypertension after 20 weeks of pregnancy; a systemic disease of the later stages of pregnancy that affects about 5 - 10% of all pregnancies and is the most common, yet least understood disorder of pregnancy. It is a rapidly progressive condition characterized by high blood pressure, platelet aggregation, swelling of the lower extremities and protein in urine. It is one of the most dangerous complications of pregnancy, and it remains an important cause of feto-maternal morbidity and mortality, particularly in developing countries where it accounts for a significant cause of maternal deaths.

The role of APLA in the aetiopathogenesis of obstetric complications such as recurrent spontaneous miscarriages has been well established. Women with APS are known to have increased risk of developing preeclampsia however the role of APLA in preeclampsia in general is still unclear. Preeclampsia generally is associated with serious maternal and fetal complications such as DIC, abruptio placent, maternal deaths and adverse fetal outcome. APLA positivity may not be accountable for the adverse events. Several publications have associated antiphospholipid antibodies with miscarriage-ages, retarded intrauterine growth and others with preeclampsia although this latter correlation remains controversial.

In this study women who had preeclampsia among them 17(17%) were positive for APLA and among control only 5(5%) women were positive for APLA. However a statistically significant association was seen between preeclampsia and APLA. i.e. (p-value=0.007) Women with preeclampsia had OR=3.89 times more chances of having APLA positive in them.

CONCLUSION

Results of this study showed a significant association and significant risk between APLA and preeclampsia. Therefore a routine assay of APLA in women at risk of preeclampsia should be done. However APLA testing should be considered in women with early onset severe preeclampsia, especially when additional clinical features of APS are present.

REFERENCES

1. Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 2011;128(1):77-85.
2. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. The Lancet 2010;376(9751):1498-509.
3. Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep 2007;9(3):219-25.
4. Fischer-Betz R, Specker C, Brinks R, Schneider M. Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus 2012;21(11):1183-9.
5. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp K, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. Br Med J 2010;340(7756):1125-32.
6. Salehi R, Asl AA, Alizadeh M, Sayyahmelli M, Azarfarin R. Comparison of Antiphospholipid Antibodies in Hypertensive with Normotensive Pregnant Women. Rawal Med J 2007;32:173-5.
7. Benedict N, Augustina AO, Emefiele AM, Alexander NI. Antiphospholipid Antibodies in Women with Preeclampsia Seen at the University of Benin Teaching Hospital, Benin City, Nigeria. Int J Health Sci Res 2014;4(2):140-8.
8. Dreyfus M, Hedelin G, Kutnahorsky R, Lehmann B, Langer B, et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstet Gynecol 2001;97(1):29-34.
9. Laganà AS, Favilli A, Triolo O, Graneze R, Gerli S. Early serum markers of pre-eclampsia: are we stepping forward? The Journal of Maternal-Fetal & Neonatal Medicine 2015;1:5.
10. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstetrics and gynecology 2003;102(1):181-92.
11. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. American journal of obstetrics and gynecology 1996;175(5):1365-70.
12. Vatten LJ, Skjærven R. Is pre-eclampsia more than one disease? BJOG: an International Journal of Obstetrics & Gynaecology 2004;111(4):298-302.
13. Villar J, Betran A, Gulmezoglu M. Epidemiological basis for the planning of maternal health services. WHO/RHR 2001;111:298-02.
14. Khedun S, Moodley J, Naicker T, Maharaj B. Drug management of hypertensive disorders of pregnancy. Pharmacology & therapeutics 1997;74(2):221-58.
15. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: lessons learned from recent trials. American journal of obstetrics and gynecology 2004;190(6):1520-6.
16. Obstetricians ACo, Gynecologists. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstetrics and gynecology 2013;122(5):1122.
17. Program NHBPE. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. American journal of obstetrics and gynecology 2000;183(1):s1-s22.
18. Rodriguez-Thompson D, Lieberman ES. Use of a random urinary protein-to-creatinine ratio for the diagnosis of significant proteinuria during pregnancy. American journal of obstetrics and gynecology 2001;185(4):808-11.
19. Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. Journal of pregnancy 2012;2012.
20. Steegers EA, von Dadelszen P, Dudevot JJ, Pijnenborg R. Pre-eclampsia. The Lancet 2010;376(9741):631-44.
21. Organization WH. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. 2011.
22. Organization WH. The World health report: 2005: make every mother and child count: overview. 2005.

PROFORMA
Association of Antiphospholipid Antibodies (APLA) with Preeclampsia (PE) in females presenting for Antenatal Check-up

Case#: Date:
Reg. no:
Name: W/O:
Age: Gestational age:
Parity:
Address:

Study group: Case (with PE) □ Control (without PE) □
APLA: Positive □ Negative □

Cite this Article: Farsom Ayub, Maryam Talib, Muhammad Arslan Iqbal (2022). Association between Antiphospholipid Antibodies (APLA) and Preeclampsia (PE) in Females Presenting for Antenatal Check-Up. International Journal of Current Science Research and Review, 5(6), 2039-2044